TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Nasal Airway Obstruction Using the Aerin Medical Device

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Seeking treatment for nasal obstruction and willing to undergo an office-based procedure~* Nasal Obstruction Symptom Evaluation (NOSE) score of ≥ 60 at Baseline~* Nasal valve is a primary or significant contributor to the subject's nasal obstruction as determined by the study investigator (based on clinical presentation, physical examination, nasal endoscopy, etc.) and the subject has a positive response to any of the following temporary measures (based on patient history or office exam):~* Use of external nasal dilator strips (e.g., Breathe Right Strips)~* Q-Tip test (manual intranasal lateralization)~* Use of nasal stents~* Cottle Maneuver (manual lateral retraction of the cheek)~Exclusion Criteria:~* Prior surgical treatment of the nasal valve~* Rhinoplasty, septoplasty, inferior turbinate reduction or other surgical nasal procedures within the past twelve (12) months~* Chronic sinusitis, recurrent sinusitis, or allergies leading to nasal obstruction~* Septal deviation, turbinate hypertrophy, polyps, or ptotic nose tip believed to be a significant contributor to the subject's nasal obstruction symptoms~* Known or suspected allergies or contraindications for any general or local anesthetic agents and / or any antibiotic medications~* Known or suspected to be pregnant, or is lactating~* Other medical conditions which in the opinion of the investigator could predispose the subject to poor wound healing or increased surgical risk

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Vivaer Stylus (Type: EXPERIMENTAL): Intervention: Procedure: thermal treatment of submucosal tissue including cartilage in the internal nasal valve area

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Patient-Reported Outcome Of Facial Erythema (PROOF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects age of 18 years or older~* A clinical diagnosis of facial rosacea~* A Patient Self-Assessment score of 4 (severe) at Baseline prior to the study drug application~* A Clinician's Erythema Assessment (CEA) score of 3 (moderate) or 4 (severe) at Baseline prior to the study drug application~Exclusion Criteria:~* More than 5 facial inflammatory lesions (papules or pustules) of rosacea~* Any uncontrolled chronic or serious disease or medical condition that may either interfere with the interpretation of the clinical trial results, or put the subject at significant risk if the subject participates in the clinical trial as judged by the investigator~* Known or suspected allergies or sensitivities to any component of the study drugs, including the active ingredient brimonidine tartrate (see Investigator's Brochure)~* Female who is pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Brimonidine tartrate 0.5% gel (Type: EXPERIMENTAL): Participants applied brimonidine tartrate 0.5% gel topically once daily for 8 days.
- Vehicle (Type: PLACEBO_COMPARATOR): Participants applied brimonidine tartrate vehicle gel topically once daily for 8 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: (DIASMOKE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 2 diabetic patients (≤ 75 years of age) who are regular smokers (≥10 cigs/day during the past year, with no period of abstinence greater than three months in the past year) and willing to quit.~2. Females of non childbearing potential (surgically sterilized or at least 2 years postmenopausal) who are not nursing may be included. Females of childbearing potential may be included provided that they are not pregnant, not nursing, and are practicing effective contraception.~3. Subjects must be able to be outpatients and be assessed in a clinic setting.~4. Participating subjects must be able to provide written informed consent.~Exclusion Criteria:~1. Subjects currently or within the past 12 months requiring treatment for depression. Subjects with a past or present history of panic disorder, psychosis, or bipolar disorder;~2. Subjects with a current or recent (within the past 12 months) history of alcoholism;~3. Subjects with a requirement to use other medications during the study that might interfere with the evaluation of the study drug (e.g., nicotine replacement therapy);~4. Subjects with a body mass index (BMI) less than 15 or greater than 38, wearing indoor clothing without shoes and determined using the Body Mass Index (BMI);~5. Subjects with evidence or history of clinically significant allergic (except for seasonal allergies at time of dosing), endocrine, gastrointestinal, hematological, hepatic, neurologic, pulmonary, or renal disease or a history of cancer (excluding treated basal cell carcinoma and squamous cell carcinoma). Exceptions to this exclusion may include subjects with a history of mild chronic obstructive pulmonary disease, and stable thyroid disease.~6. Subjects with a history of clinically significant cardiovascular disease. In addition, subjects with uncontrolled hypertension or a screening or baseline systolic blood pressure greater than 160 mm Hg or a diastolic blood pressure greater than 95 mm Hg will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- varenicline (Type: ACTIVE_COMPARATOR): varenicline 1 mg BID. The duration of active treatment will be 12 weeks.
- control group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: This Study Is To Determine If Inhaled Insulin Is Effective In Treating Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 30 years and ≤ 75 years with a diagnosis of type 2 diabetes mellitus made \> 6 months prior to study entry~* Screening HbA1c \> 7.0%~* Currently treated on a stable dose of at least 2 oral antidiabetic agents for at least 3 months prior to study entry; including a sulfonylurea and/or metformin, and/or a thiazolidinedione~Exclusion Criteria:~Smoking within last 6 months PFTs outside of range~* Type 1 diabetes mellitus~* Type 2 diabetes mellitus currently (last three months) treated with an insulin regimen (alone or with Oral Antidiabetic Agents)~* Active liver disease; significantly-impaired hepatic function, as shown by, but not limited to, alanine aminotransferase (ALT) serum glutamic pyruvic transaminase (SGPT) or aspartate transaminase (AST) serum glutamic-oxaloacetic transaminase (SGOT) above 2x the upper limit of normal as measured at visit 1. However, patients with elevated ALT \>1.5 upper limit of normal as a result of hepatic steatosis are permitted to enter the study.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Insulin glargine (Type: ACTIVE_COMPARATOR): Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
- Exubera (Type: EXPERIMENTAL): Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with biopsy proven ulcerative colitis (UC), including those with inadequately controlled UC (flare) as defined by failure of standard medical therapy, steroid-dependence, and/or need for escalation of medical care as determined by severity index (Mayo Score), endoscopic or histologic study, and/or medical provider~* Have active disease, defined with a Mayo Score \> 3 and Mayo endoscopic subscore \>1~* Subjects whom the investigator believes can and will comply with the requirements of the protocol~* Able to provide informed written consent.~Exclusion Criteria:~* Biopsy-proven Crohn's disease or indeterminate colitis~* Acute abdomen or other clinical emergencies requiring emergent management (for example: stricture, bowel obstruction, perforation and/or abscess)~* Primary sclerosing cholangitis (PSC)~* Pregnancy~* Concurrent Clostridium difficile infection or other known infection~* Prior history of fecal microbiota transplantation~* Other causes of diarrhea, including but not limited to tube feeds and medications (for example, kayaxelate, metformin, lactulose, laxatives, magnesium)~* Major congenital defects~* Subjects with recent malignancy in the last 5 years, excluding non-melanoma skin malignancies~* Anaphylactic reactions to any foods~* Any antibiotic use within the last 3 months~* Subject having any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of the participant participating in the study, would make it unlikely for the participant to complete the study, or would confound the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fecal Microbiota Transplantation (Type: EXPERIMENTAL): Individuals with Ulcerative Colitis will undergo a fecal microbiota transplantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Palliation of Dyspnea in Advanced Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* We define advanced COPD as including those with severe COPD by CTS criteria (i.e., severe shortness of breath resulting in the patient being too breathless to leave the house, or breathlessness after dressing/undressing (i.e., Medical Research Council (MRC) score of 5), or the presence of chronic respiratory failure (PaCO2\>45) or clinical signs of right heart failure).~* We will also include patients who are short of breath and stop walking after about 100 meters or a few minutes on the level (MRC score 4) with at least one the following:~  * BMI \< 21;~ * post-bronchodilator FEV1 \< 30% predicted;~ * one or more hospital admissions for acute exacerbation of COPD in the previous year.~* MRC 4 patients will be recruited only if their baseline Chronic Respiratory Questionnaire - dyspnea domain (CRQ-D) score is \< 5, an entry criterion used in a Canadian RCT involving patients with advanced lung disease.~Exclusion Criteria:~* Patients and/or caregivers with cognitive or other difficulties that would preclude questionnaire completion.~* Inability to speak or understand English.~* Patients considered to be dying or with an expected survival of less than 2 months.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Morphine, low dose, in addition to conventional treatment (Type: EXPERIMENTAL): Morphine dose titration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate the Relative Bioavailability, Influence of Pantoprazole Coadministration and Food Effect of Different Oral Formulation of BI 113608

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion criteria:~1. healthy male subjects~Exclusion criteria:~1. Any relevant deviation from healthy conditions

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 BI 113608 (Type: ACTIVE_COMPARATOR): powder in the bottle for oral solution, oral administration with 240 mL water
- 2 BI 113608 (Type: EXPERIMENTAL): conventional tablet formulation
- 3 BI 113608 (Type: EXPERIMENTAL): conventional tablet formulation, fed
- 4 BI 113608 (Type: EXPERIMENTAL): conventional tablet after pantoprazole administration
- 5 BI 113608 (Type: EXPERIMENTAL): conventional tablet formulation, fasted, 0:30 min before fat breakfast

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aged at least 18 years of age; male or female. A patient who is 70 years of age or older may be considered for enrollment after review of patient clinical and laboratory data by the Protocol Medical Monitor.~* Histologically confirmed diagnosis of GBM.~* Contrast enhancing disease on MRI within 21 days prior to screening.~* Karnofsky score (KPS) of ≥ 60 at Screening.~* No prior RT, chemotherapy (including Gliadel wafer), immunotherapy or therapy with a biologic agent, or hormonal therapy. Glucocorticoid therapy is allowed.~* Within 2 weeks of baseline visit, hematologic and renal functions as specified: Absolute neutrophil count ≥ 1500/mm3, platelets ≥ 100,000/mm3, Hgb ≥ 9.0g/dL, creatinine ≤ 1.7mg/dl, total bilirubin ≤ 1.5mg/dL, blood urea nitrogen (BUN) within 2 times the upper limit of normal, transaminases ≤ 4 times above the upper limits of the institutional norm.~* Sexually active patients must use an acceptable method of contraception while receiving doses of study medication.~* Females of childbearing potential must have a negative serum or urine pregnancy test at screening and have additional pregnancy tests during study.~Exclusion Criteria:~* Patient who cannot undergo MRI.~* Pregnant or lactating.~* Serious concurrent infection or medical illness that would jeopardize the ability of the patient to receive study treatment with reasonable safety.~* Patient receiving concurrent chemotherapeutics or investigational agents within 30 days of baseline assessments, including gliadel wafers or gliasite application.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TSC 0.25 mg/kg for 9 or 18 doses (Type: EXPERIMENTAL): This was an open-label, sequential-cohort, dose-escalation study in two phases. Phase 1 was a safety run-in evaluating Trans Sodium Crocetinate (TSC) in 3 subjects who received 3 doses per week for 3 weeks (9 doses in total). Phase 2 engaged 56 subjects who received 3 doses per week for 6 weeks (18 doses in total). TSC was consistently dosed at 0.25mg/kg in both phases.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Effectiveness of Decision Support Strategies for Joint Replacement Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of either hip or knee osteoarthritis~* Scheduled visit with participating orthopedic surgeon~Exclusion Criteria:~* prior partial or total knee or hip joint replacement within last 5 years~* hip fracture or asceptic necrosis (AVN) in last 12 months~* Rheumatoid arthritis~* Psoriatic arthritis~* Unable to read English or Spanish~* Unable to consent for self due to cognitive or medical issue~* Hip or knee decision aid provided by Partners Healthcare clinician within 12 months

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Interactive Decision Aid and Usual Care (Type: EXPERIMENTAL): Group receiving brief interactive decision aid and being seen by a provider assigned to usual care. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise.
- Video decision aid and usual care (Type: EXPERIMENTAL): Group receiving long video decision aids and being seen by a provider assigned to usual care. The decision aids are the DVD and Booklets for hip and knee osteoarthritis from Health Dialog.
- Interactive Decision Aid and Provider Report (Type: EXPERIMENTAL): Group receiving brief interactive decision aid and being seen by a provider assigned to intervention arm. The decision aids are the Shared Decision Points for hip and knee osteoarthritis from Healthwise. The provider intervention is a report that includes the patients' goals and treatment preferences.
- Video decision aid and Provider report (Type: EXPERIMENTAL): Group receiving long video decision aids and being seen by a provider assigned to intervention arm. The decision aids are the hip or knee DVD and Booklets for hip and knee osteoarthritis from Health Dialog. The intervention is a report that includes the patients' goals and treatment preferences.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provided informed consent (emergency consent according to local regulations where approved)~2. Age 18 to 75 years (inclusive)~3. Admitted to an intensive care unit~4. Treatment with High Flow Nasal Oxygen, non-invasive ventilation or invasive mechanical ventilation for acute respiratory failure caused by COVID-19 for less than 48 hours~5. A PaO2:FiO2 ratio of \<200mmHg (\<26.7kPa) with a FiO2 ≥0.6~6. Confirmed laboratory diagnosis of COVID-19 within 7 days of meeting screening criteria~Exclusion Criteria:~1. Known pregnancy (positive urine or serum pregnancy test)~2. Ongoing treatment with an immunomodulatory agent not included in the standard of care for COVID-19 (including participation in clinical trials of such agents).~3. Body mass index (BMI) ≥ 40 kg/m2or weight ≥ 130 kg~4. Anticipated transfer to another hospital, which is not a study site within 72 hours~5. Expected to die within 6 months of treatment due to underlying chronic disease~6. Limitations of care in place during current hospital admission~   -

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- nangibotide (Type: EXPERIMENTAL): Continuous infusion of experimental agent for up to 120 hours
- placebo (Type: PLACEBO_COMPARATOR): Continuous infusion of matched placebo for up to 120 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Infusion of a Local Anaesthetic in the Surgical After Modified Radical Mastectomy With Expander

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with operable breast cancer, which will be submitted to modified radical mastectomy~* Sign informed consent.~Exclusion Criteria:~1. Mastectomy without lymphadenectomy~2. Over 80 years~3. Cognitive impairment and patients with serious psychiatric disorders before diagnosis of the cancer process~4. Severe liver or kidney disease~5. Patients allergic or intolerant to any of the drugs used in the study protocol.~6. Regular users of analgesics or narcotics

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Women of this group be infused saline 2 ml / h for 48h.
- levo-bupicaine (Type: EXPERIMENTAL): Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete